Skip to main content

Table 1 Tumor clinico-pathological features, cytology, and RNA yields of the patients.

From: The effects of timing of fine needle aspiration biopsies on gene expression profiles in breast cancers

Patient No. Tumor Type Tumor Size
(cm)
Tumor Grade ER* PR* HER2* Positive Nodes PRE Total RNA
(μg)
PRE Tumor Cell
(%)
POST Total RNA
(μg)
POST Tumor Cell
(%)
1 IDC 2.8/2.6 2 & 3 + + + 2–26 9.6 >99 15.4 >99
2 IDC 1.9 3 + + - 0/12 0.8 >99 1.4 >99
3 IDC 2 3 + + - 1–17 0.4 >99 9.8 >99
4 IDC 1.6 3 + + - 1–4 1.9 >99 1.4 >99
5 IDC 3 2 + - - 0/16 0.2 >99 1 **
6 IDC 15 3 + + - 29/32 0.5 >99 1.8 >99
7 IDC 4.5 3 - - + 0/11 7.6 >99 30.4 >99
8 IDC 1.6 2 + + - 0/16 1.4 >99 3.7 >99
9 IDC 1.7 3 - - - 1–18 2 >99 1.1 >99
10 IDC 2.2/1.0 3 - - + 2–17 7.5 >99 3.4 >99
11 IDC/lobular 6.5 2 + + - 8–15 1.5 >99 3.2 >99
12 IDC 2.5 3 - - - 8–25 1.3 ** 12.4 >99
13 IDC 4 2 + + - 2–20 4.2 >99 8.5 >99
14 IDC 6.5 2 - - + 1–12 9.5 >99 3.2 >99
15 IDC 2.1 2 + + - 0/3 1.2 >99 9.6 50
16 IDC 3.4 2 + + - 0/3 1.9 >99 0.4 >99
  1. ER, estrogen receptor; PR, progesterone receptor; HER2, Her2/neu receptor status; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.*ER, PR, and HER2 status as reported on standard surgical pathology reports were determined by immunohistochemistry, or by fluorescent in situ hybridization (FISH) for HER2 according to our institutional standard of practice. ** Cytology from FNABs of patient 5 POST and 12 PRE could not be determined due to low cellularity in the cytologic fractions.